Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
UPDATE: Cantor Fitzgerald Starts I-Mab (IMAB) at Overweight
-
The Lupus Research Alliance Launches the ManyOne Can. Walk with Us to Cure Lupus Virtual Experience to Support Lupus Research
-
Caledonia Mining Corporation Plc: Block Listing Application and "At The Market" Sales Agreement
-
Caledonia Mining Corporation Plc: Block Listing Application and "At The Market" Sales Agreement
-
Cantor Fitzgerald Said 'Just the Beginning' of CymaBay Therapeutic (CBAY) Share Recovery After FDA Hold Lifted
-
Cantor Fitzgerald Reiterates Overweight Rating on Pfizer (PFE)
-
ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Freddie Mac Prices $828 Million Multifamily K-Deal, K-F81
-
OrganiGram Holdings Inc (OGI:CN) (OGI) PT Lowered to Cdn$5 at Cantor Fitzgerald, Following Earnings
-
Buy Emergent BioSolutions (EBS) on Index Rebalancing Weakness - Cantor Fitzgerald
-
Molecular Templates (MTEM) Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility
-
Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility
-
A Better Financial Plan, LLC., Announces Settlement With The Securities And Exchange Commission After Three-Year Investigation
-
Evolent Health (EVH) PT Raised to $10 at Cantor Fitzgerald on Asset Sale
-
Companies with NDRs 7/17
-
UPDATE: Cantor Fitzgerald Starts Curis (CRIS) at Overweight
-
Cytokinetics (CYTK) Prices 7.29M Share Common Offering at $24/Sh
-
ALX Oncology Holdings Inc. (ALXO) Prices 8.5M Share IPO at $19/Sh
-
Cytokinetics Announces Pricing of Public Offering of Common Stock
-
ALX Oncology Announces Pricing of Initial Public Offering
-
ALX Oncology Announces Pricing of Initial Public Offering
-
Emergent BioSolutions (EBS) PT Raised to $110 at Cantor Fitzgerald
-
Companies with NDRs 7/16
-
Orchid Island Capital Announces Estimated Second Quarter 2020 Results, July 2020 Monthly Dividend and June 30, 2020 RMBS Portfolio Characteristics
-
Cytokinetics (CYTK) Announces Proposed $150M Share Common Offering
-
Cytokinetics Announces Proposed Public Offering of Common Stock
-
UnitedHealth Group (UNH) PT Raised to $350 at Cantor Fitzgerald, Following Earnings
-
Aphria Inc. (APHA:CN) (APHA) PT Raised to Cdn$10.50 at Cantor Fitzgerald
-
Form 13F-HR CANTOR FITZGERALD INVEST For: Jun 30
-
Northern Dynasty Announces Closing of US$35.3 Million Bought Deal
-
Companies with NDRs 7/15
-
UPDATE: Cantor Fitzgerald Starts Soliton (SOLY) at Overweight
-
Cantor Fitzgerald Reiterates Overweight Rating on BiomX (PHGE) Following KOL Call
-
Gossamer Bio Inc. (GOSS) PT Raised to $33 at Cantor Fitzgerald; 'GB004 has best-in-class potential'
-
Cantor Fitzgerald Assumes Brainsway (BWAY) at Overweight
-
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cantor Fitzgerald Downgrades Benefytt Technologies (BFYT) to Neutral
-
Companies with NDRs 7/13
-
Haymaker and ARKO Holdings Ltd. and GPM Investments, LLC Sign Non-Binding Letter of Intent for a Business Combination
-
Haymaker and ARKO Holdings Ltd. and GPM Investments, LLC Sign Non-Binding Letter of Intent for a Business Combination
-
Northern Dynasty Increases Previously Announced Bought Deal to US$30.7 Million
-
Cantor Fitzgerald Said Amarin (AMRN) NDR Supports Bullish Rating, PT
-
Northern Dynasty Announces US$25 Million Bought Deal And Up To US$7.5 Million Concurrent Private Placement
-
Otonomy (OTIC) Announces Pricing of $60.1 Million Public Offering of Common Stock, Warrants
-
Otonomy Announces Pricing of $60.1 Million Public Offering
-
Cantor Fitzgerald Starts Amryt (AMYT) at Overweight
-
Otonomy (OTIC) Commences Public Offering of Common Stock
-
Otonomy Announces Proposed Public Offering

